Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 2/20 | 0.56 |
| ▸ | MMP9 | P14780 | 2/20 | 0.56 |
| ▸ | MMP7 | P09237 | 1/20 | 0.56 |
| ▸ | MMP12 | P39900 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | MME | P08473 | 3/20 | 0.55 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.55 |
| ▸ | REN | P00797 | 2/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2519489 | 1.00 | ACE (0.56) | ACEMMP2MMP9MMP7MMP12 | |
| SCHEMBL29582587 | 0.96 | ACE (0.52) | ACEMMP2MMP9MMP7MMP12 | |
| Glycylleucylphenylalanine SCHEMBL4281374 | 0.92 | ACE (0.62) | ACEMMP2MMP9MMP7MMP12 | |
| Glycylleucylphenylalanine SCHEMBL4281369 | 0.92 | ACE (0.62) | ACEMMP2MMP9MMP7MMP12 | |
| SCHEMBL9829182 | 0.92 | MME (0.64) | ACEMMP2MMP9MMP7MMP12 | |
| SCHEMBL5370772 | 0.92 | MME (0.64) | ACEMMP2MMP9MMP7MMP12 | |
| SCHEMBL9551455 | 0.92 | MME (0.64) | ACEMMP2MMP9MMP7MMP12 | |
| SCHEMBL18173548 | 0.90 | MME (0.53) | ACEMMP2MMP9MMP7MMP12 | |
| SCHEMBL29365781 | 0.90 | MME (0.53) | ACEMMP2MMP9MMP7MMP12 | |
| SCHEMBL18173547 | 0.90 | MME (0.53) | ACEMMP2MMP9MMP7MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030506-B2 | Tumor selective and biodegradable cyclotriphosphazene-platinum(II) conjugate anticancer agent, and preparation method thereof | NANOHYBRID CO., LTD (KR) | 2011-10-04 | — | — | US | claimed |
| US-20100249226-A1 | TUMOR SELECTIVE AND BIODEGRADABLE CYCLOTRIPHOSPHAZENE-PLATINUM(II) CONJUGATE ANTICANCER AGENT, AND PREPARATION METHOD THEREOF | NANOHYBRID CO., LTD (KR) | 2010-09-30 | — | — | US | claimed |
| EP-2137200-A1 | TUMOR SELECTIVE AND BIODEGRADABLE CYCLOTRIPHOSPHAZENE-PLATINUM(II) CONJUGATE ANTICANCER AGENT, AND PREPARATION METHOD THEREOF | Nanohybrid Co., Ltd. (KR) | 2009-12-30 | — | — | EP | claimed |
| WO-2008130121-A1 | TUMOR SELECTIVE AND BIODEGRADABLE CYCLOTRIPHOSPHAZENE-PLATINUM(II) CONJUGATE ANTICANCER AGENT, AND PREPARATION METHOD THEREOF | NANOHYBRID CO., LTD. (KR) | 2008-10-30 | — | — | WO | claimed |
| CN-101715454-A | Tumor selective and biodegradable cyclotriphosphazene-platinum(II) conjugate anticancer agent, and preparation method thereof | NANOHYBRID CO LTD | 2010-05-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249226-A1 | TUMOR SELECTIVE AND BIODEGRADABLE CYCLOTRIPHOSPHAZENE-PLATINUM(II) CONJUGATE ANTICANCER AGENT, AND PREPARATION METHOD THEREOF | PHOSPHO1, TYMP, PAICS | ACE 3270/4885MMP2 884/4885MMP9 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.